keyword
MENU ▼
Read by QxMD icon Read
search

Palivizumab

keyword
https://www.readbyqxmd.com/read/28425254/wheezing-asthma-and-atopy-in-premature-infants-at-2-years-of-age
#1
Sevim Ünal, Ayşenur Kaya, Leyla Bilgin, Emine Misirlioğlu, Can Naci Kocabaş
BACKGROUND/AIM: We aimed to evaluate wheezing, bronchial asthma (BA), and atopy in premature infants at 2 years of age via a cross-sectional study. MATERIALS AND METHODS: Premature infants at <37 weeks of gestational age (GA) were assessed for atopy by skin-prick test and serum immunoglobulin E level at 2 years of age. The family's and infant's histories of allergy, BA, atopy, and wheezing were obtained by questionnaire and from hospital records. RESULTS: There were 98 infants, with mean birth weight (BW) 1517...
April 18, 2017: Turkish Journal of Medical Sciences
https://www.readbyqxmd.com/read/28423192/systematic-review-of-the-safety-and-efficacy-of-palivizumab-among-infants-and-young-children-with-cystic-fibrosis
#2
Kok Pim Kua, Shaun Wen Huey Lee
BACKGROUND: Respiratory syncytial virus (RSV) is a common pathogen in infants with cystic fibrosis (CF). The use of palivizumab prophylaxis for RSV infection as the standard of care for infants with CF remains controversial. OBJECTIVE: To evaluate the efficacy of palivizumab in reducing the incidence of RSV hospitalization in children with CF who are younger than 2 years of age. METHODS: Four electronic databases (PubMed, Embase, CINAHL, and CENTRAL) were searched from inception until January 31, 2017 for clinical studies investigating the use of palivizumab in infants with CF aged less than 2 years...
April 19, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/28414106/molecular-evolution-of-the-fusion-protein-f-gene-in-human-respiratory-syncytial-virus-subgroup-b
#3
Hirokazu Kimura, Koo Nagasawa, Ryusuke Kimura, Hiroyuki Tsukagoshi, Yuki Matsushima, Kiyotaka Fujita, Eiko Hirano, Naruhiko Ishiwada, Takako Misaki, Kazunori Oishi, Makoto Kuroda, Akihide Ryo
In this study, we examined the molecular evolution of the fusion protein (F) gene in human respiratory syncytial virus subgroup B (HRSV-B). First, we performed time-scale evolution analyses using the Bayesian Markov chain Monte Carlo (MCMC) method. Next, we performed genetic distance, linear B-cell epitope prediction, N-glycosylation, positive/negative selection site, and Bayesian skyline plot analyses. We also constructed a structural model of the F protein and mapped the amino acid substitutions and the predicted B-cell epitopes...
April 14, 2017: Infection, Genetics and Evolution
https://www.readbyqxmd.com/read/28413427/immunogenicity-and-safety-of-a-respiratory-syncytial-virus-fusion-protein-rsv-f-nanoparticle-vaccine-in-older-adults
#4
Louis Fries, Vivek Shinde, Jeffrey J Stoddard, D Nigel Thomas, Eloi Kpamegan, Hanxin Lu, Gale Smith, Somia P Hickman, Pedro Piedra, Gregory M Glenn
BACKGROUND: A preventative strategy for Respiratory Syncytial Virus (RSV) infection constitutes an under-recognized unmet medical need among older adults. Four formulations of a novel recombinant RSV F nanoparticle vaccine (60 or 90 μg RSV F protein, with or without aluminum phosphate adjuvant) administered concurrently with a licensed inactivated trivalent influenza vaccine (TIV) in older adult subjects were evaluated for safety and immunogenicity in this randomized, observer-blinded study...
2017: Immunity & Ageing: I & A
https://www.readbyqxmd.com/read/28403044/comparing-first-and-second-year-palivizumab-prophylaxis-in-patients-with-hemodynamically-significant-congenital-heart-disease-in-the-caress-database-2005-2015
#5
MULTICENTER STUDY
Abby Li, Daniel Y Wang, Krista L Lanctôt, Ian Mitchell, Bosco A Paes
BACKGROUND: Respiratory syncytial virus hospitalization (RSVH) rates in children <2 years of age with hemodynamically significant congenital heart disease (HSCHD) are 2- to 4-fold higher compared with healthy term infants. Pediatric recommendations differ as to whether palivizumab is beneficial beyond 1 year of age. The objective of this study was to determine whether differences exist in respiratory-related illness hospitalization (RIH) and RSVH in HSCHD infants receiving palivizumab during the first year versus second year of life in the Canadian Registry of Palivizumab...
May 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/28391538/efficacy-of-palivizumab-prophylaxis-on-the-frequency-of-rsv-associated-lower-respiratory-tract-infections-in-preterm-infants-determination-of-the-ideal-target-population-for-prophylaxis
#6
M Cetinkaya, T K Oral, S Karatekin, B Cebeci, A Babayigit, Y Yesil
Respiratory syncytial virus (RSV) prophylaxis in high-risk infants is an effective intervention for the prevention of severe disease. The aim of this study was to determine the ideal target preterm population that might benefit from palivizumab prophylaxis by establishing the main risk factors for acute RSV-related infections. Former premature infants born with a gestational age ≤37 weeks and ≤1 year of age at the beginning of the RSV season and admitted with respiratory infection were included. RSV status was evaluated by RSV strip test in all infants...
April 8, 2017: European Journal of Clinical Microbiology & Infectious Diseases
https://www.readbyqxmd.com/read/28381595/rsv-hospitalizations-in-comparison-with-regional-rsv-activity-and-inpatient-palivizumab-administration-2010-2013
#7
Alexander F Glick, Stephanie Kjelleren, Annika M Hofstetter, Anupama Subramony
OBJECTIVES: To compare pediatric respiratory syncytial virus (RSV) hospitalizations in the United States to regional RSV activity and inpatient palivizumab administration. METHODS: We characterized inpatients, excluding newborns, with RSV from the Pediatric Health Information System (July 2010-June 2013). RSV regional activity timing was defined by the National Respiratory and Enteric Virus Surveillance System. RSV hospitalization season (defined by at least 3 SDs more than the mean regional baseline number of RSV hospitalizations for 3 consecutive weeks) was compared with RSV regional activity season (2 consecutive weeks with ≥10% RSV-positive testing)...
April 5, 2017: Hospital Pediatrics
https://www.readbyqxmd.com/read/28348428/respiratory-syncytial-virus-infection-rates-with-limited-use-of-palivizumab-for-infants-born-at-29-to-31-6-7-weeks-gestational-age
#8
Brandi Newby, Todd Sorokan
BACKGROUND: Immunoprophylaxis with palivizumab can reduce respiratory syncytial virus (RSV) infections and hospitalizations. Criteria in British Columbia limit the use of palivizumab to infants born at 29 to 31+6/7 weeks gestational age, which differ from guidelines of the American Academy of Pediatrics (AAP) and the Canadian Paediatric Society (CPS). OBJECTIVE: To determine whether the limited use of palivizumab affected the frequency of hospital visits by RSV-positive infants (termed "RSV-positive hospital visits") who received approval for palivizumab and those who met the AAP/CPS criteria but did not receive approval for palivizumab...
January 2017: Canadian Journal of Hospital Pharmacy
https://www.readbyqxmd.com/read/28324595/recent-advances-in-developing-antiviral-therapies-for-respiratory-syncytial-virus
#9
REVIEW
Brian C Shook, Kai Lin
Respiratory syncytial virus (RSV) infection presents a significant health challenge in small children, the elderly and immunocompromised patients. There is still a high unmet medical need among patients with RSV infection, and no specific antiviral therapy is available. The only approved agents are palivizumab, which has to be given prophylactically, mainly in high-risk infants, and ribavirin, which is rarely used due to toxicity concerns and questionable benefits. Efforts to develop new antiviral agents have been hampered by the perceived need for high safety hurdles in pediatric patient populations use and the lack of well-characterized druggable targets...
April 2017: Topics in Current Chemistry (Journal)
https://www.readbyqxmd.com/read/28303835/trends-of-respiratory-syncytial-virus-sub-types-in-children-hospitalised-at-a-tertiary-care-centre-in-jaipur-during-2012-2014
#10
M Anjaneya Swamy, Bharti Malhotra, P V Janardhan Reddy, Jitendra Kumar Tiwari, Neeraj Kumar, Manohar Lal Gupta
Respiratory syncytial virus (RSV) causes high mortality and morbidity in infants. The study was planned to determine the trends of RSV sub-types in hospitalised children. Nasopharyngeal aspirate and throat swabs were collected from the hospitalised children up to 5 years of age. Viral nucleic acid was extracted using easyMAG automated extraction system, and real-time reverse transcription polymerase chain reaction was performed. Total positivity for RSV was found to be 25.40%, predominantly for RSV B (20.03%), followed by RSV A (2...
January 2017: Indian Journal of Medical Microbiology
https://www.readbyqxmd.com/read/28276287/benzimidazole-based-derivatives-as-privileged-scaffold-developed-for-the-treatment-of-the-rsv-infection-a-computational-study-exploring-the-potency-and-cytotoxicity-profiles
#11
Elena Cichero, Michele Tonelli, Federica Novelli, Bruno Tasso, Ilenia Delogu, Roberta Loddo, Olga Bruno, Paola Fossa
Respiratory syncytial virus (RSV) has been identified as a main cause of hospitalisation in infants and children. To date, the current therapeutic arsenal is limited to ribavirin and palivizumab with variable efficacy. In this work, starting from a number of in-house series of previously described anti-RSV agents based on the benzimidazole scaffold, with the aim at gaining a better understanding of the related chemical features involved in potency and safety profiles, we applied a computational study including two focussed comparative molecular fields analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA)...
December 2017: Journal of Enzyme Inhibition and Medicinal Chemistry
https://www.readbyqxmd.com/read/28275185/broadly-reactive-anti-rsv-g-antibodies-from-exposed-individuals-effectively-inhibit-infection-of-primary-airway-epithelial-cells
#12
B Cortjens, E Yasuda, X Yu, K Wagner, Y B Claassen, A Q Bakker, J B M van Woensel, T Beaumont
Respiratory syncytial virus (RSV) causes severe respiratory disease in young children. Antibodies specific for the RSV prefusion F protein have guided RSV vaccine research and in human serum these antibodies attribute to >90% of the neutralization response, however detailed insight in the composition of the human B cell repertoire against RSV is still largely unknown. In order to study the B cell repertoire of 3 healthy donors for specificity against RSV, CD27(+) memory B cells were isolated and immortalized using BCL6 and Bcl-xL...
March 8, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28273842/immunological-features-of-respiratory-syncytial-virus-caused-pneumonia-implications-for-vaccine-design
#13
REVIEW
Emma Rey-Jurado, Alexis M Kalergis
The human respiratory syncytial virus (hRSV) is the causative agent for high rates of hospitalizations due to viral bronchiolitis and pneumonia worldwide. Such a disease is characterized by an infection of epithelial cells of the distal airways that leads to inflammation and subsequently to respiratory failure. Upon infection, different pattern recognition receptors recognize the virus and trigger the innate immune response against the hRSV. Further, T cell immunity plays an important role for virus clearance...
March 4, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28236796/cost-effectiveness-of-a-protocol-using-palivizumab-in-preterm-infants
#14
Yolanda Hernández-Gago, Marina Lombardero-Pin, Casilda Ortega de la Cruz, Pablo A Maciuniak, Alicia Díez Del Pino
OBJECTIVE: The main objective was to evaluate the cost-effectiveness of protocol use of palivizumab in premature established by consensus in our Hospital comparing it based on the recommendations of various Scientific Societies. As a secondary objective risk factors and severity of hospitalized patients attending the established protocol in our Hospital were analyzed. METHODS: The study period was 4 seasons with the expanded protocol (retrospective data) versus 2 with restricted or agreed protocol (prospective data)...
March 1, 2017: Farmacia Hospitalaria
https://www.readbyqxmd.com/read/28236418/one-year-observational-study-of-palivizumab-prophylaxis-on-infants-at-risk-for-respiratory-syncytial-virus-infection-in-latin-america
#15
Leandro Martin Castillo, Gabriela Bugarin, Juan Carlos Arias, Jairo Israel Barajas Rangel, Maria Elina Serra, Nestor Vain
OBJECTIVE: This study aims to describe real world palivizumab use and effectiveness in high-risk Latin American infants and young children. METHOD: Prospective, multicenter observational study with infants at risk for severe RSV infection who received palivizumab according to routine clinical practice. Subjects were followed for one year with monthly visits after the first dose of palivizumab. An infant was considered adherent if receiving all the expected injections or five or fewer injections within appropriate inter-dose intervals...
February 22, 2017: Jornal de Pediatria
https://www.readbyqxmd.com/read/28219614/palivizumab-prophylaxis-in-preterm-infants
#16
Paul Kiet Tang
No abstract text is available yet for this article.
February 14, 2017: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/28188494/palivizumab-exposure-and-the-risk-of-atopic-dermatitis-asthma-and-allergic-rhinoconjunctivitis-a-cross-national-population-based-cohort-study
#17
Ann Haerskjold, Lonny Stokholm, Marie Linder, Simon Francis Thomsen, Gunnar Bergman, Ingegärd Anveden Berglind, Helle Kieler, Henrik Ravn, Lone Graff Stensballe
BACKGROUND: Palivizumab is a humanized monoclonal antibody designed to provide passive immunity against respiratory syncytial virus. It is prescribed to children at high risk for severe infection with respiratory syncytial virus. However, little is known about the risk of the immune-mediated diseases atopic dermatitis, asthma, and allergic rhinoconjunctivitis after palivizumab exposure. AIM: Our objective was to investigate whether exposure to palivizumab was associated with atopic dermatitis, asthma, or allergic rhinoconjunctivitis in childhood...
April 2017: Paediatric Drugs
https://www.readbyqxmd.com/read/28187117/in-reply-statistical-power-to-detect-an-association-between-guideline-based-palivizumab-administration-and-hospitalizations-for-respiratory-syncytial-virus-infections
#18
Carlina J Grindeland, David D Leedahl
No abstract text is available yet for this article.
March 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/28187116/statistical-power-to-detect-an-association-between-guideline-based-palivizumab-administration-and-hospitalizations-for-respiratory-syncytial-virus-infections
#19
Christopher S Ambrose
No abstract text is available yet for this article.
March 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/28163166/respiratory-syncytial-virus-hospitalizations-in-infants-of-28-weeks-gestational-age-and-less-in-the-palivizumab-era
#20
Bernhard Resch, Beatrice Egger, Stefan Kurath-Koller, Berndt Urlesberger
OBJECTIVE: To obtain data on respiratory syncytial virus (RSV) associated hospitalization rates in preterm infants of 28 weeks gestational age and less in the era of palivizumab prophylaxis. METHODS: Retrospective single-center cohort study including all preterm infants up to 28 weeks+6days gestational age and born between 2004 and 2012 at a tertiary care university hospital. Data on RSV related hospitalizations over the first two years of life covering at least two RSV seasons (November-April) were analyzed...
February 2, 2017: International Journal of Infectious Diseases: IJID
keyword
keyword
44503
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"